INmune Bio, Inc. (INMB)

INmune Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-42.08	-30.01	-27.3	-30.34	-12.1
Other Amortization	0.08	0.22	0.24	0.13	-
Asset Writedown & Restructuring Costs	-	-	0.09	-	-
Stock-Based Compensation	7.61	7.37	7.15	4.8	3.11
Change in Accounts Payable	-1.37	2.72	1.4	2.26	1.08
Change in Other Net Operating Assets	2.41	7.72	-4.27	-5.35	-1.03
Operating Cash Flow	-33.36	-11.98	-22.69	-28.5	-8.94
Other Investing Activities	-	-	-	-15	-
Investing Cash Flow	-	-	-	-15	-
Long-Term Debt Issued	-	-	-	14.95	-
Total Debt Issued	-	-	-	14.95	-
Long-Term Debt Repaid	-10	-5	-	-	-
Net Debt Issued (Repaid)	-10	-5	-	14.95	-
Issuance of Common Stock	28.21	0.78	0.73	81.41	24.91
Repurchase of Common Stock	-	-	-	-	-1.01
Financing Cash Flow	18.21	-4.23	0.73	96.36	23.9
Foreign Exchange Rate Adjustments	0.22	-0.1	-0.7	-0.01	0.02
Net Cash Flow	-14.93	-16.31	-22.66	52.84	14.97
Cash Interest Paid	1.69	1.78	1.37	0.56	-
Levered Free Cash Flow	-18.45	-1.4	-13.27	-16.53	-4.73
Unlevered Free Cash Flow	-18.03	-0.2	-12.25	-16.66	-4.73
Change in Net Working Capital	-1.01	-11.02	3.18	3.23	0.2

Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q